In addition, activation of the PERK pathway is required for breast cancer cells that have undergone an EMT to survive treatment of doxorubicin and paclitaxel, primarily through the NRF2 cascade, a non-canonical downstream of PERK22. The gene discussed is EIF2AK3; the disease is breast cancer.